Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. Co. utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). Co. is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers. We show 11 historical shares outstanding datapoints in our coverage of MTEM's shares outstanding history.
Understanding the changing numbers of MTEM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MTEM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MTEM by allowing them to research MTEM shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
